Adaptive Biotechnologies Corp (ADPT): R&D Expense
$93.77M
Year ended 2025-12-31
$88.21M
Trailing 12 months to 2026-06-30
-12.9%
3-year compound annual growth
-4.2%
5-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $93.77M | -8.9% | 2026-02-26, From 2025-01-01 |
| 2024-12-31 | $102.95M | -15.7% | 2026-02-26, From 2024-01-01 |
| 2023-12-31 | $122.12M | -13.9% | 2026-02-26, From 2023-01-01 |
| 2022-12-31 | $141.76M | -0.4% | 2025-03-03, From 2022-01-01 |
| 2021-12-31 | $142.34M | +22.6% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $116.07M | +64.2% | 2023-02-14, From 2020-01-01 |
| 2019-12-31 | $70.70M | +80.6% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $39.16M | +22.4% | 2021-02-24, From 2018-01-01 |
| 2017-12-31 | $32.00M | n/a | 2020-02-26, From 2017-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | $93.77M | -8.9% |
| Vericel Corp (VCEL) | 2025-12-31 | $27.56M | +11.2% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | $300.27M | +8.7% |
| Vaxart, Inc. (VXRT) | 2025-12-31 | $201.58M | +171.6% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | $80.28M | -11.6% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $58.05M | +8.3% |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | $274.87M | +23.7% |
| Adaptimmune Therapeutics PLC (ADAPY) | 2024-12-31 | $149.06M | +17.8% |
| REGENXBIO Inc. (RGNX) | 2025-12-31 | $228.30M | +9.5% |
Compare ADPT, VCEL, IOVA, VXRT side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗